| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peritoneal Neoplasms | 9 | 2025 | 46 | 5.830 |
Why?
|
| Colorectal Neoplasms | 12 | 2025 | 581 | 4.200 |
Why?
|
| Appendiceal Neoplasms | 6 | 2025 | 19 | 3.840 |
Why?
|
| Cytoreduction Surgical Procedures | 9 | 2025 | 45 | 3.430 |
Why?
|
| Hyperthermia, Induced | 5 | 2023 | 56 | 2.800 |
Why?
|
| Adenocarcinoma | 9 | 2025 | 1029 | 2.550 |
Why?
|
| Circulating Tumor DNA | 2 | 2025 | 35 | 1.730 |
Why?
|
| Microbiota | 3 | 2023 | 395 | 1.680 |
Why?
|
| Gastrointestinal Microbiome | 5 | 2024 | 719 | 1.610 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2021 | 154 | 1.440 |
Why?
|
| Rectal Neoplasms | 4 | 2025 | 78 | 1.250 |
Why?
|
| Biomarkers, Tumor | 7 | 2025 | 1559 | 1.170 |
Why?
|
| Pancreatic Neoplasms | 4 | 2021 | 698 | 1.070 |
Why?
|
| Combined Modality Therapy | 8 | 2025 | 1251 | 1.040 |
Why?
|
| Melanoma | 5 | 2022 | 942 | 1.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 5 | 2025 | 196 | 0.900 |
Why?
|
| Survival Rate | 11 | 2025 | 2070 | 0.890 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 2023 | 2 | 0.850 |
Why?
|
| Hepatectomy | 1 | 2024 | 112 | 0.840 |
Why?
|
| B7-H1 Antigen | 2 | 2020 | 122 | 0.810 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2022 | 82 | 0.740 |
Why?
|
| Neoplasm Metastasis | 1 | 2024 | 711 | 0.720 |
Why?
|
| Laparoscopy | 4 | 2025 | 495 | 0.720 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 80 | 0.710 |
Why?
|
| Humans | 60 | 2025 | 126330 | 0.680 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2021 | 74 | 0.680 |
Why?
|
| Appendicitis | 1 | 2021 | 128 | 0.660 |
Why?
|
| Neutropenia | 1 | 2021 | 197 | 0.660 |
Why?
|
| Mesothelioma | 1 | 2020 | 89 | 0.640 |
Why?
|
| Prognosis | 10 | 2025 | 4742 | 0.610 |
Why?
|
| Stomach Neoplasms | 2 | 2024 | 550 | 0.600 |
Why?
|
| Neoplasm Proteins | 2 | 2020 | 685 | 0.590 |
Why?
|
| Biguanides | 1 | 2017 | 13 | 0.570 |
Why?
|
| Lactams | 1 | 2017 | 19 | 0.570 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2025 | 160 | 0.570 |
Why?
|
| Digoxin | 1 | 2017 | 43 | 0.560 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 2106 | 0.540 |
Why?
|
| Retrospective Studies | 17 | 2025 | 16517 | 0.520 |
Why?
|
| Karyopherins | 1 | 2016 | 36 | 0.520 |
Why?
|
| Longevity | 1 | 2017 | 150 | 0.510 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2016 | 124 | 0.510 |
Why?
|
| Caenorhabditis elegans | 1 | 2017 | 231 | 0.510 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2017 | 178 | 0.500 |
Why?
|
| Neoplasms | 6 | 2024 | 2807 | 0.480 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 4 | 2022 | 91 | 0.480 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2023 | 1262 | 0.470 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 592 | 0.460 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2020 | 379 | 0.460 |
Why?
|
| Autophagy | 1 | 2017 | 402 | 0.450 |
Why?
|
| Cell Survival | 4 | 2021 | 835 | 0.450 |
Why?
|
| Metabolic Syndrome | 1 | 2017 | 346 | 0.440 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 1334 | 0.430 |
Why?
|
| Cell Nucleus | 1 | 2016 | 673 | 0.430 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2023 | 37 | 0.420 |
Why?
|
| Neoadjuvant Therapy | 3 | 2025 | 347 | 0.420 |
Why?
|
| Middle Aged | 19 | 2025 | 27031 | 0.420 |
Why?
|
| Carcinogenesis | 3 | 2022 | 345 | 0.400 |
Why?
|
| Lung Neoplasms | 3 | 2020 | 1668 | 0.390 |
Why?
|
| Mutation | 6 | 2025 | 5965 | 0.380 |
Why?
|
| MAP Kinase Signaling System | 4 | 2017 | 315 | 0.380 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2025 | 747 | 0.380 |
Why?
|
| Aged | 18 | 2025 | 19962 | 0.370 |
Why?
|
| Signal Transduction | 7 | 2023 | 4638 | 0.360 |
Why?
|
| Mice | 14 | 2023 | 17881 | 0.340 |
Why?
|
| Carrier Proteins | 2 | 2006 | 1029 | 0.330 |
Why?
|
| ral GTP-Binding Proteins | 2 | 2021 | 4 | 0.310 |
Why?
|
| Robotic Surgical Procedures | 2 | 2025 | 208 | 0.310 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2020 | 355 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 495 | 0.290 |
Why?
|
| Immunity, Innate | 2 | 2011 | 375 | 0.290 |
Why?
|
| Lymph Node Excision | 2 | 2024 | 164 | 0.290 |
Why?
|
| Female | 25 | 2025 | 67333 | 0.290 |
Why?
|
| Lymphatic Metastasis | 3 | 2025 | 420 | 0.280 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2016 | 569 | 0.270 |
Why?
|
| Animals | 16 | 2023 | 34533 | 0.270 |
Why?
|
| Male | 21 | 2025 | 62031 | 0.260 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2004 | 210 | 0.260 |
Why?
|
| Ubiquitin | 2 | 2004 | 143 | 0.260 |
Why?
|
| Fecal Microbiota Transplantation | 2 | 2024 | 97 | 0.260 |
Why?
|
| Microsatellite Instability | 2 | 2025 | 38 | 0.250 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 921 | 0.250 |
Why?
|
| Adult | 12 | 2025 | 29802 | 0.250 |
Why?
|
| Androgen Receptor Antagonists | 2 | 2023 | 36 | 0.240 |
Why?
|
| Lysosomes | 2 | 2017 | 245 | 0.240 |
Why?
|
| Liquid Biopsy | 1 | 2025 | 14 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2025 | 1171 | 0.230 |
Why?
|
| Synthetic Lethal Mutations | 1 | 2024 | 10 | 0.230 |
Why?
|
| HeLa Cells | 3 | 2017 | 796 | 0.230 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2025 | 362 | 0.230 |
Why?
|
| SUMO-1 Protein | 1 | 2004 | 8 | 0.220 |
Why?
|
| Follow-Up Studies | 7 | 2025 | 5204 | 0.220 |
Why?
|
| Nerve Growth Factor | 1 | 2004 | 21 | 0.220 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2025 | 193 | 0.220 |
Why?
|
| Xenopus Proteins | 1 | 2004 | 60 | 0.220 |
Why?
|
| RNA, Small Interfering | 3 | 2016 | 677 | 0.210 |
Why?
|
| RNA Interference | 3 | 2016 | 512 | 0.210 |
Why?
|
| Antineoplastic Agents | 3 | 2023 | 1725 | 0.210 |
Why?
|
| ras Proteins | 1 | 2004 | 137 | 0.200 |
Why?
|
| Operating Rooms | 1 | 2023 | 68 | 0.200 |
Why?
|
| Dysbiosis | 1 | 2024 | 124 | 0.200 |
Why?
|
| Receptors, Androgen | 2 | 2023 | 415 | 0.200 |
Why?
|
| Immunotherapy | 3 | 2022 | 685 | 0.200 |
Why?
|
| Surgical Stapling | 1 | 2022 | 18 | 0.200 |
Why?
|
| Neoplasms, Second Primary | 1 | 2024 | 143 | 0.190 |
Why?
|
| Lymph Nodes | 1 | 2024 | 380 | 0.190 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2023 | 89 | 0.190 |
Why?
|
| Aged, 80 and over | 6 | 2025 | 6645 | 0.190 |
Why?
|
| Peritoneum | 1 | 2022 | 37 | 0.190 |
Why?
|
| Immune System | 1 | 2022 | 91 | 0.190 |
Why?
|
| Molecular Targeted Therapy | 2 | 2022 | 379 | 0.190 |
Why?
|
| Anastomosis, Surgical | 1 | 2022 | 166 | 0.190 |
Why?
|
| Dietary Fiber | 1 | 2021 | 76 | 0.190 |
Why?
|
| CTLA-4 Antigen | 1 | 2021 | 62 | 0.180 |
Why?
|
| Platinum Compounds | 1 | 2020 | 6 | 0.180 |
Why?
|
| Pemetrexed | 1 | 2020 | 9 | 0.180 |
Why?
|
| Suture Techniques | 1 | 2022 | 196 | 0.180 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2021 | 44 | 0.170 |
Why?
|
| Perfusion | 1 | 2022 | 206 | 0.170 |
Why?
|
| Cell Line, Tumor | 6 | 2021 | 3449 | 0.170 |
Why?
|
| Portal Vein | 1 | 2021 | 91 | 0.170 |
Why?
|
| Enzyme Activation | 4 | 2006 | 631 | 0.170 |
Why?
|
| Thrombospondin 1 | 1 | 2020 | 23 | 0.170 |
Why?
|
| Bacteria | 1 | 2024 | 486 | 0.170 |
Why?
|
| Emergencies | 1 | 2021 | 173 | 0.170 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 129 | 0.170 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2020 | 48 | 0.170 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2020 | 55 | 0.170 |
Why?
|
| Viruses | 1 | 2021 | 121 | 0.170 |
Why?
|
| Oncogenes | 1 | 2020 | 173 | 0.160 |
Why?
|
| Biopsy | 1 | 2023 | 1257 | 0.160 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 424 | 0.160 |
Why?
|
| Membrane Proteins | 2 | 2004 | 1551 | 0.160 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 293 | 0.160 |
Why?
|
| Gene Expression | 1 | 2004 | 1560 | 0.160 |
Why?
|
| Probiotics | 1 | 2021 | 220 | 0.150 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2021 | 438 | 0.150 |
Why?
|
| Surgeons | 1 | 2023 | 258 | 0.150 |
Why?
|
| Down-Regulation | 1 | 2020 | 689 | 0.150 |
Why?
|
| Genomics | 2 | 2020 | 1538 | 0.140 |
Why?
|
| Starvation | 1 | 2017 | 15 | 0.140 |
Why?
|
| Autophagosomes | 1 | 2017 | 27 | 0.140 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 1135 | 0.140 |
Why?
|
| Up-Regulation | 1 | 2020 | 874 | 0.140 |
Why?
|
| Caloric Restriction | 1 | 2017 | 86 | 0.140 |
Why?
|
| I-kappa B Kinase | 1 | 2017 | 62 | 0.140 |
Why?
|
| High-Throughput Screening Assays | 1 | 2017 | 100 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2022 | 558 | 0.140 |
Why?
|
| Follistatin-Related Proteins | 1 | 2016 | 2 | 0.130 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2016 | 35 | 0.130 |
Why?
|
| Porphyrins | 1 | 2016 | 17 | 0.130 |
Why?
|
| Genes, Lethal | 1 | 2016 | 76 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2021 | 1413 | 0.130 |
Why?
|
| Cell Differentiation | 1 | 2004 | 1931 | 0.130 |
Why?
|
| Endosomes | 1 | 2016 | 65 | 0.130 |
Why?
|
| Diet, High-Fat | 1 | 2017 | 212 | 0.130 |
Why?
|
| Fatty Liver | 1 | 2017 | 191 | 0.130 |
Why?
|
| Transfection | 2 | 2011 | 1073 | 0.120 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2016 | 454 | 0.120 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2011 | 625 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2017 | 745 | 0.120 |
Why?
|
| Prostatic Neoplasms | 2 | 2023 | 1551 | 0.120 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2015 | 4 | 0.120 |
Why?
|
| Gene Regulatory Networks | 2 | 2024 | 369 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2024 | 1987 | 0.120 |
Why?
|
| Lipid Metabolism | 1 | 2017 | 356 | 0.120 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2014 | 31 | 0.120 |
Why?
|
| Phosphoproteins | 1 | 2016 | 423 | 0.110 |
Why?
|
| HCT116 Cells | 2 | 2011 | 55 | 0.110 |
Why?
|
| Glycolysis | 1 | 2014 | 154 | 0.110 |
Why?
|
| NF-kappa B | 1 | 2016 | 469 | 0.110 |
Why?
|
| Treatment Outcome | 5 | 2025 | 12380 | 0.110 |
Why?
|
| Prospective Studies | 2 | 2023 | 6175 | 0.110 |
Why?
|
| Cell Proliferation | 2 | 2020 | 2394 | 0.100 |
Why?
|
| Nuclear Proteins | 2 | 2016 | 1280 | 0.100 |
Why?
|
| Multiprotein Complexes | 2 | 2021 | 211 | 0.100 |
Why?
|
| Phosphorylation | 2 | 2021 | 1640 | 0.100 |
Why?
|
| Mitochondria | 1 | 2017 | 696 | 0.100 |
Why?
|
| Calcium | 1 | 2017 | 1111 | 0.100 |
Why?
|
| Muscle Proteins | 1 | 2014 | 416 | 0.090 |
Why?
|
| Biomarkers | 1 | 2021 | 3153 | 0.090 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2012 | 86 | 0.090 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2011 | 20 | 0.090 |
Why?
|
| Cryosurgery | 1 | 2011 | 47 | 0.090 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 2071 | 0.090 |
Why?
|
| Intestinal Obstruction | 1 | 2012 | 93 | 0.090 |
Why?
|
| Liver | 1 | 2017 | 1758 | 0.090 |
Why?
|
| Cell Line | 3 | 2004 | 2734 | 0.080 |
Why?
|
| Protein Binding | 3 | 2021 | 1749 | 0.080 |
Why?
|
| Exome | 1 | 2015 | 1039 | 0.080 |
Why?
|
| Salvage Therapy | 1 | 2011 | 189 | 0.080 |
Why?
|
| Apoptosis | 3 | 2020 | 1839 | 0.080 |
Why?
|
| Cystectomy | 1 | 2010 | 161 | 0.080 |
Why?
|
| Transcription Factors | 2 | 2016 | 2618 | 0.080 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2010 | 179 | 0.080 |
Why?
|
| Catheter Ablation | 1 | 2011 | 233 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2015 | 1512 | 0.070 |
Why?
|
| Endoscopy | 1 | 2010 | 282 | 0.070 |
Why?
|
| Palliative Care | 1 | 2012 | 440 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 2 | 2025 | 625 | 0.070 |
Why?
|
| Rats | 2 | 2004 | 3763 | 0.070 |
Why?
|
| Precipitin Tests | 2 | 2004 | 156 | 0.070 |
Why?
|
| Kidney Neoplasms | 1 | 2011 | 440 | 0.070 |
Why?
|
| Vesicular Transport Proteins | 1 | 2006 | 120 | 0.060 |
Why?
|
| Abdominal Injuries | 1 | 2007 | 115 | 0.060 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2010 | 530 | 0.060 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2025 | 21 | 0.060 |
Why?
|
| Protein Kinases | 2 | 2004 | 332 | 0.060 |
Why?
|
| Cells, Cultured | 1 | 2011 | 3040 | 0.060 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2007 | 213 | 0.060 |
Why?
|
| Smad4 Protein | 1 | 2025 | 57 | 0.060 |
Why?
|
| Receptor, Notch1 | 1 | 2025 | 66 | 0.060 |
Why?
|
| Stomach | 1 | 2007 | 270 | 0.060 |
Why?
|
| Colectomy | 1 | 2025 | 74 | 0.060 |
Why?
|
| PC12 Cells | 1 | 2004 | 25 | 0.060 |
Why?
|
| CA-19-9 Antigen | 1 | 2024 | 10 | 0.060 |
Why?
|
| Colorectal Surgery | 1 | 2004 | 9 | 0.060 |
Why?
|
| CA-125 Antigen | 1 | 2024 | 15 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2004 | 19 | 0.050 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2024 | 22 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2022 | 1517 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 1300 | 0.050 |
Why?
|
| Neurites | 1 | 2004 | 42 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2024 | 4874 | 0.050 |
Why?
|
| Xenopus laevis | 1 | 2004 | 127 | 0.050 |
Why?
|
| Chromatography, Affinity | 1 | 2003 | 70 | 0.050 |
Why?
|
| Substrate Specificity | 1 | 2004 | 292 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 771 | 0.050 |
Why?
|
| Protein Subunits | 1 | 2004 | 166 | 0.050 |
Why?
|
| beta Catenin | 1 | 2025 | 216 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2004 | 343 | 0.050 |
Why?
|
| Age of Onset | 1 | 2025 | 608 | 0.050 |
Why?
|
| DNA Primers | 1 | 2004 | 659 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2023 | 128 | 0.050 |
Why?
|
| Plasmids | 1 | 2004 | 514 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2004 | 336 | 0.050 |
Why?
|
| Needs Assessment | 1 | 2004 | 176 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 4466 | 0.050 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2002 | 90 | 0.050 |
Why?
|
| DNA Mismatch Repair | 1 | 2022 | 47 | 0.050 |
Why?
|
| Plant Proteins | 1 | 2002 | 82 | 0.050 |
Why?
|
| Microfilament Proteins | 1 | 2004 | 280 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 121 | 0.050 |
Why?
|
| Health Status Disparities | 1 | 2024 | 230 | 0.050 |
Why?
|
| Melanoma, Experimental | 1 | 2021 | 35 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2021 | 36 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2004 | 1110 | 0.050 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2021 | 31 | 0.050 |
Why?
|
| eIF-2 Kinase | 1 | 2021 | 35 | 0.050 |
Why?
|
| Cholangiography | 1 | 2021 | 15 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 867 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2003 | 467 | 0.050 |
Why?
|
| Cytosol | 1 | 2021 | 163 | 0.040 |
Why?
|
| Binding Sites | 1 | 2004 | 1305 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 1073 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2004 | 475 | 0.040 |
Why?
|
| Fluorescence | 1 | 2021 | 96 | 0.040 |
Why?
|
| Coloring Agents | 1 | 2021 | 79 | 0.040 |
Why?
|
| Cholecystectomy | 1 | 2021 | 61 | 0.040 |
Why?
|
| Indocyanine Green | 1 | 2021 | 58 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2021 | 164 | 0.040 |
Why?
|
| Cell Cycle | 2 | 2015 | 612 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 1399 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 1712 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 446 | 0.040 |
Why?
|
| Proteomics | 1 | 2003 | 513 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 307 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2023 | 435 | 0.040 |
Why?
|
| Morbidity | 2 | 2012 | 248 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2020 | 595 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2006 | 3777 | 0.040 |
Why?
|
| Virus Diseases | 1 | 2021 | 281 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 3901 | 0.040 |
Why?
|
| Communication | 1 | 2023 | 521 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 1064 | 0.040 |
Why?
|
| Feces | 1 | 2021 | 732 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 2542 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 566 | 0.040 |
Why?
|
| MAP Kinase Kinase 4 | 2 | 2011 | 38 | 0.040 |
Why?
|
| Kidney | 1 | 2004 | 1361 | 0.030 |
Why?
|
| Buffers | 1 | 2016 | 31 | 0.030 |
Why?
|
| BRCA2 Protein | 1 | 2015 | 45 | 0.030 |
Why?
|
| Genome, Human | 2 | 2013 | 1304 | 0.030 |
Why?
|
| Retinoblastoma Protein | 1 | 2015 | 81 | 0.030 |
Why?
|
| Genes, myc | 1 | 2015 | 105 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 859 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2015 | 236 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2014 | 107 | 0.030 |
Why?
|
| Risk Factors | 2 | 2025 | 10375 | 0.030 |
Why?
|
| Cell Death | 1 | 2014 | 239 | 0.030 |
Why?
|
| Indoles | 1 | 2015 | 192 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 195 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 1722 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2015 | 270 | 0.030 |
Why?
|
| Systems Biology | 1 | 2013 | 58 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 1725 | 0.020 |
Why?
|
| North Carolina | 1 | 2012 | 59 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2004 | 3078 | 0.020 |
Why?
|
| Models, Biological | 2 | 2010 | 1469 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 499 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 369 | 0.020 |
Why?
|
| DNA Repair | 1 | 2015 | 589 | 0.020 |
Why?
|
| Ohio | 1 | 2011 | 87 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 67 | 0.020 |
Why?
|
| Genes, ras | 1 | 2011 | 98 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 579 | 0.020 |
Why?
|
| Laparoscopes | 1 | 2010 | 3 | 0.020 |
Why?
|
| Stochastic Processes | 1 | 2010 | 37 | 0.020 |
Why?
|
| Urinary Diversion | 1 | 2010 | 44 | 0.020 |
Why?
|
| Telomerase | 1 | 2011 | 169 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2011 | 348 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2011 | 214 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 375 | 0.020 |
Why?
|
| Pelvis | 1 | 2010 | 68 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 70 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2010 | 217 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 975 | 0.020 |
Why?
|
| United States | 1 | 2025 | 10990 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2010 | 290 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 1768 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 1291 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 595 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1111 | 0.020 |
Why?
|
| Time Factors | 2 | 2011 | 6334 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2010 | 771 | 0.020 |
Why?
|
| Shock, Traumatic | 1 | 2007 | 7 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 1038 | 0.020 |
Why?
|
| Michigan | 1 | 2007 | 47 | 0.020 |
Why?
|
| Trauma Severity Indices | 1 | 2007 | 79 | 0.020 |
Why?
|
| Computational Biology | 1 | 2010 | 838 | 0.020 |
Why?
|
| Urban Population | 1 | 2007 | 230 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2004 | 76 | 0.010 |
Why?
|
| Streptavidin | 1 | 2003 | 4 | 0.010 |
Why?
|
| Biotinylation | 1 | 2003 | 21 | 0.010 |
Why?
|
| Microspheres | 1 | 2003 | 72 | 0.010 |
Why?
|
| Algorithms | 1 | 2010 | 1647 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 321 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 1789 | 0.010 |
Why?
|
| Laparotomy | 1 | 2004 | 136 | 0.010 |
Why?
|
| Sorbitol | 1 | 2002 | 8 | 0.010 |
Why?
|
| MAP Kinase Kinase 7 | 1 | 2002 | 11 | 0.010 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2002 | 47 | 0.010 |
Why?
|
| RNA, Double-Stranded | 1 | 2002 | 64 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2002 | 93 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2002 | 109 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2002 | 309 | 0.010 |
Why?
|
| Proteome | 1 | 2003 | 257 | 0.010 |
Why?
|
| Ligands | 1 | 2002 | 543 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2002 | 303 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 3622 | 0.010 |
Why?
|
| Length of Stay | 1 | 2004 | 1325 | 0.010 |
Why?
|
| Drosophila | 1 | 2002 | 792 | 0.010 |
Why?
|
| Incidence | 1 | 2004 | 3170 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2004 | 3461 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2007 | 14221 | 0.010 |
Why?
|
| Adolescent | 1 | 2007 | 19548 | 0.000 |
Why?
|
| Child | 1 | 2007 | 24766 | 0.000 |
Why?
|